ProCE Banner Activity

The Evolving Treatment of Early Breast Cancer: Expert Answers to FAQs

Clinical Thought

Get expert answers to healthcare professional questions on current dilemmas in treating early breast cancer, including using adjuvant ribociclib, deciding between olaparib and abemaciclib, and de-escalating chemotherapy.

Released: July 25, 2023

Share

Faculty

Joyce O'Shaughnessy

Joyce O'Shaughnessy, MD

Celebrating Women Chair in Breast Cancer Research
Baylor University Medical Center
Chair, Breast Disease Committee
Texas Oncology
Sarah Cannon Research Institute
Dallas, Texas

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by educational grants from AstraZeneca and Merck Sharp & Dohme LLC.

AstraZeneca

Merck Sharp & Dohme, LLC

Faculty Disclosure

Primary Author

Joyce O'Shaughnessy, MD

Celebrating Women Chair in Breast Cancer Research
Baylor University Medical Center
Chair, Breast Disease Committee
Texas Oncology
Sarah Cannon Research Institute
Dallas, Texas

Joyce O'Shaughnessy, MD: consultant/advisor: AbbVie Inc., Agendia, Aptitude Health, AstraZeneca, Bayer, Bristol-Myers Squibb, Caris, Carrick Therapeutics, Celgene Corporation, Daiichi Sankyo, Eisai, Exact Sciences, Fishawack Health, G1 Therapeutics, GlaxoSmithKline, Genentech, Gilead Sciences, Immunomedics, Incyte Corporation, Lilly, Loxo Oncology, Merck, Novartis, Ontada, Pfizer, Pharmacyclics, Pierre Fabre Pharmaceuticals, Puma Biotechnology, Prime Oncology, Roche, Samsung Bioepis, Sanofi, Seagen, Stemline Therapeutics, Theralink, Synthon, Veru.